Table of Contents

1 Report Overview

• 1.1 Definition and Specification
• 1.2 Report Overview
  • 1.2.1 Manufacturers Overview
  • 1.2.2 Regions Overview
  • 1.2.3 Type Overview
  • 1.2.4 Application Overview
• 1.3 Industrial Chain
  • 1.3.1 Pulmonary Drugs Overall Industrial Chain
  • 1.3.2 Upstream
  • 1.3.3 Downstream
• 1.4 Industry Situation
  • 1.4.1 Industrial Policy
  • 1.4.2 Product Preference
  • 1.4.3 Economic/Political Environment
• 1.5 SWOT Analysis

2 Market Analysis by Types

• 2.1 Overall Market Performance(Volume)
  • 2.1.1 Inhaled Corticosteroids (ICS) Market Performance (Volume)
  • 2.1.2 Long-Acting Beta2-Agonists (LABA) Market Performance (Volume)
  • 2.1.3 Antihistamine Market Performance (Volume)
  • 2.1.4 Vasodilators Market Performance (Volume)
  • 2.1.5 Short-Acting Beta2-Agonists (SABA) Market Performance (Volume)
• 2.2 Overall Market Performance(Value)
  • 2.1.1 Inhaled Corticosteroids (ICS) Market Performance (Value)
  • 2.1.2 Long-Acting Beta2-Agonists (LABA) Market Performance (Value)
  • 2.1.3 Antihistamine Market Performance (Value)
  • 2.1.4 Vasodilators Market Performance (Value)
  • 2.1.5 Short-Acting Beta2-Agonists (SABA) Market Performance (Value)

3 Product Application Market

• 3.1 Overall Market Performance (Volume)
  • 3.1.1 Asthma & COPD Market Performance (Volume)
  • 3.1.2 Allergic Rhinitis Market Performance (Volume)
  • 3.1.3 Pulmonary Arterial Hypertension Market Performance (Volume)
  • 3.1.4 Cystic Fibrosis Market Performance (Volume)

4 Manufacturers Profiles/Analysis

• 4.1 AstraZeneca plc
  • 4.1.1 AstraZeneca plc Profiles
  • 4.1.2 AstraZeneca plc Product Information
  • 4.1.3 AstraZeneca plc Pulmonary Drugs Business Performance
  • 4.1.4 AstraZeneca plc Pulmonary Drugs Business Development and Market Status
• 4.2 Bayer AG?
  • 4.2.1 Bayer AG? Profiles
  • 4.2.2 Bayer AG? Product Information
  • 4.2.3 Bayer AG? Pulmonary Drugs Business Performance
  • 4.2.4 Bayer AG? Pulmonary Drugs Business Development and Market Status
• 4.3 Teva Pharmaceutical Industries Ltd.?
  • 4.3.1 Teva Pharmaceutical Industries Ltd.? Profiles
  • 4.3.2 Teva Pharmaceutical Industries Ltd.? Product Information
  • 4.3.3 Teva Pharmaceutical Industries Ltd.? Pulmonary Drugs Business Performance
  • 4.3.4 Teva Pharmaceutical Industries Ltd.? Pulmonary Drugs Business Development and Market Status
• 4.4 Actelion Pharmaceuticals, Inc.
  • 4.4.1 Actelion Pharmaceuticals, Inc. Profiles
  • 4.4.2 Actelion Pharmaceuticals, Inc. Product Information
  • 4.4.3 Actelion Pharmaceuticals, Inc. Pulmonary Drugs Business Performance
  • 4.4.4 Actelion Pharmaceuticals, Inc. Pulmonary Drugs Business Development and Market Status
• 4.5 Boehringer Ingelheim GmbH
  • 4.5.1 Boehringer Ingelheim GmbH Profiles
  • 4.5.2 Boehringer Ingelheim GmbH Product Information
  • 4.5.3 Boehringer Ingelheim GmbH Pulmonary Drugs Business Performance
  • 4.5.4 Boehringer Ingelheim GmbH Pulmonary Drugs Business Development and Market Status
• 4.6 F. Hoffmann-La Roche Ltd.
  • 4.6.1 F. Hoffmann-La Roche Ltd. Profiles
  • 4.6.2 F. Hoffmann-La Roche Ltd. Product Information
  • 4.6.3 F. Hoffmann-La Roche Ltd. Pulmonary Drugs Business Performance
  • 4.6.4 F. Hoffmann-La Roche Ltd. Pulmonary Drugs Business Development and Market Status
• 4.7 Merck & Co., Inc.
  • 4.7.1 Merck & Co., Inc. Profiles
  • 4.7.2 Merck & Co., Inc. Product Information
  • 4.7.3 Merck & Co., Inc. Pulmonary Drugs Business Performance
  • 4.7.4 Merck & Co., Inc. Pulmonary Drugs Business Development and Market Status
• 4.8 Novartis AG
  • 4.8.1 Novartis AG Profiles
  • 4.8.2 Novartis AG Product Information
  • 4.8.3 Novartis AG Pulmonary Drugs Business Performance
  • 4.8.4 Novartis AG Pulmonary Drugs Business Development and Market Status
• 4.9 GlaxoSmithKline plc
  • 4.9.1 GlaxoSmithKline plc Profiles
  • 4.9.2 GlaxoSmithKline plc Product Information
  • 4.9.3 GlaxoSmithKline plc Pulmonary Drugs Business Performance
  • 4.9.4 GlaxoSmithKline plc Pulmonary Drugs Business Development and Market Status
• 4.10 Sunovion Pharmaceuticals, Inc.?
  • 4.10.1 Sunovion Pharmaceuticals, Inc.? Profiles
  • 4.10.2 Sunovion Pharmaceuticals, Inc.? Product Information
  • 4.10.3 Sunovion Pharmaceuticals, Inc.? Pulmonary Drugs Business Performance
  • 4.10.4 Sunovion Pharmaceuticals, Inc.? Pulmonary Drugs Business Development and Market Status

5 Market Performance for Manufacturers

• 5.1 Asia-Pacific Pulmonary Drugs Sales (K Units) and Market Share by Manufacturers 2013-2018
• 5.2 Asia-Pacific Pulmonary Drugs Revenue (M USD) and Market Share by Manufacturers 2013-2018
• 5.3 Asia-Pacific Pulmonary Drugs Price (USD/Unit) of Manufacturers 2013-2018
• 5.4 Asia-Pacific Pulmonary Drugs Gross Margin of Manufacturers 2013-2018
• 5.5 Market Concentration

6 Regions Market Performance for Manufacturers

• 6.1 China Market Performance for Manufacturers
  • 6.1.1 China Pulmonary Drugs Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.1.2 China Pulmonary Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.1.3 China Pulmonary Drugs Price (USD/Unit) of Manufacturers 2013-2018
  • 6.1.4 China Pulmonary Drugs Gross Margin of Manufacturers 2013-2018
  • 6.1.5 Market Concentration
• 6.2 Japan Market Performance for Manufacturers
  • 6.2.1 Japan Pulmonary Drugs Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.2.2 Japan Pulmonary Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.2.3 Japan Pulmonary Drugs Price (USD/Unit) of Manufacturers 2013-2018
  • 6.2.4 Japan Pulmonary Drugs Gross Margin of Manufacturers 2013-2018
  • 6.2.5 Market Concentration
• 6.3 South Korea Market Performance for Manufacturers
  • 6.3.1 South Korea Pulmonary Drugs Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.3.2 South Korea Pulmonary Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.3.3 South Korea Pulmonary Drugs Price (USD/Unit) of Manufacturers 2013-2018
  • 6.3.4 South Korea Pulmonary Drugs Gross Margin of Manufacturers 2013-2018
  • 6.3.5 Market Concentration
• 6.4 Taiwan Market Performance for Manufacturers
  • 6.4.1 Taiwan Pulmonary Drugs Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.4.2 Taiwan Pulmonary Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.4.3 Taiwan Pulmonary Drugs Price (USD/Unit) of Manufacturers 2013-2018
  • 6.4.4 Taiwan Pulmonary Drugs Gross Margin of Manufacturers 2013-2018
  • 6.4.5 Market Concentration
• 6.5 India Market Performance for Manufacturers
  • 6.5.1 India Pulmonary Drugs Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.5.2 India Pulmonary Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.5.3 India Pulmonary Drugs Price (USD/Unit) of Manufacturers 2013-2018
  • 6.5.4 India Pulmonary Drugs Gross Margin of Manufacturers 2013-2018
  • 6.5.5 Market Concentration
• 6.6 Southeast Asia Market Performance for Manufacturers
  • 6.6.1 Southeast Asia Pulmonary Drugs Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.6.2 Southeast Asia Pulmonary Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.6.3 Southeast Asia Pulmonary Drugs Price (USD/Unit) of Manufacturers 2013-2018
  • 6.6.4 Southeast Asia Pulmonary Drugs Gross Margin of Manufacturers 2013-2018
  • 6.6.5 Market Concentration
• 6.7 Australia Market Performance for Manufacturers
  • 6.7.1 Australia Pulmonary Drugs Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.7.2 Australia Pulmonary Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.7.3 Australia Pulmonary Drugs Price (USD/Unit) of Manufacturers 2013-2018
  • 6.7.4 Australia Pulmonary Drugs Gross Margin of Manufacturers 2013-2018
  • 6.7.5 Market Concentration
• 6.8 Market Performance for Manufacturers
  • 6.8.1 Pulmonary Drugs Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.8.2 Pulmonary Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.8.3 Pulmonary Drugs Price (USD/Unit) of Manufacturers 2013-2018
  • 6.8.4 Pulmonary Drugs Gross Margin of Manufacturers 2013-2018
  • 6.8.5 Market Concentration

7 Asia-Pacific Pulmonary Drugs Market Performance (Sales Point)

• 7.1 Asia-Pacific Pulmonary Drugs Sales (K Units) and Market Share by Regions 2013-2018
• 7.2 Asia-Pacific Pulmonary Drugs Revenue (M USD) and Market Share by Regions 2013-2018
• 7.3 Asia-Pacific Pulmonary Drugs Price (USD/Unit) by Regions 2013-2018
• 7.4 Asia-Pacific Pulmonary Drugs Gross Margin by Regions 2013-2018

8 Development Trend for Regions (Sales Point)

• 8.1 Asia-Pacific Pulmonary Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.2 China Pulmonary Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.3 Japan Pulmonary Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.4 South Korea Pulmonary Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.5 Taiwan Pulmonary Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.6 India Pulmonary Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.7 Southeast Asia Pulmonary Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.8 Australia Pulmonary Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.8 Australia Pulmonary Drugs Sales and Growth, Sales Value and Growth Rate2013-2018

9 Upstream Source, Technology and Cost

• 9.1 Upstream Source
• 9.2 Technology
• 9.3 Cost

10 Channel Analysis

• 10.1 Market Channel
• 10.2 Distributors

11 Consumer Analysis

• 11.1 Asthma & COPD Industry
• 11.2 Allergic Rhinitis Industry
• 11.3 Pulmonary Arterial Hypertension Industry

12 Market Forecast 2019-2024

• 12.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2019-2024
  • 12.1.1 Asia-Pacific Pulmonary Drugs Sales (K Units), Revenue (M USD) and Market Share by Regions 2019-2024
  • 12.1.2 Asia-Pacific Pulmonary Drugs Sales (K Units) and Growth Rate 2019-2024
  • 12.1.3 China Pulmonary Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.4 Japan Pulmonary Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.5 South Korea Pulmonary Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.6 Taiwan Pulmonary Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.7 India Pulmonary Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.8 Southeast Asia Pulmonary Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.9 Australia Pulmonary Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.10 Pulmonary Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
• 12.3 Sales (K Units), Revenue (M USD) by Types 2019-2024
  • 12.3.1 Overall Market Performance
  • 12.3.2 Inhaled Corticosteroids (ICS) Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.3.3 Long-Acting Beta2-Agonists (LABA) Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.3.4 Antihistamine Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.3.5 Vasodilators Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
• 12.4 Sales by Application 2019-2024
  • 12.4.1 Overall Market Performance
  • 12.4.2 Asthma & COPD Sales and and Growth Rate 2019-2024
  • 12.4.3 Allergic Rhinitis Sales and and Growth Rate 2019-2024
  • 12.4.4 Pulmonary Arterial Hypertension Sales and and Growth Rate 2019-2024
  • 12.4.5 Cystic Fibrosis Sales and and Growth Rate 2019-2024
• 12.5 Price (USD/Unit) and Gross Profit
  • 12.5.1 Asia-Pacific Pulmonary Drugs Price (USD/Unit) Trend 2019-2024
  • 12.5.2 Asia-Pacific Pulmonary Drugs Gross Profit Trend 2019-2024

13 Conclusion

Geographically, this report split Asia-Pacific into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Pulmonary Drugs for these regions, from 2012 to 2023 (forecast), including
China
Japan
South Korea
Taiwan
India
Southeast Asia
Australia

Asia-Pacific Pulmonary Drugs market competition by top manufacturers/players, with Pulmonary Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
AstraZeneca plc
Bayer AG?
Teva Pharmaceutical Industries Ltd.?
Actelion Pharmaceuticals, Inc.
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Merck & Co., Inc.
Novartis AG
GlaxoSmithKline plc
Sunovion Pharmaceuticals, Inc.?

On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into
Inhaled Corticosteroids (ICS)
Long-Acting Beta2-Agonists (LABA)
Antihistamine
Vasodilators
Short-Acting Beta2-Agonists (SABA)
Anticholinergics
? ? Combination Drugs
? ? MAbs
? ? Enzymes
? ? Antibiotics & Antileukotrienes

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Units), market share and growth rate of Pulmonary Drugs for each application, including
Asthma & COPD
Allergic Rhinitis
Pulmonary Arterial Hypertension
Cystic Fibrosis

If you have any special requirements, please let us know and we will offer you the report as you want.